By a News Reporter-Staff News Editor at Women's Health Weekly -- Fresh data on Oncology are presented in a new report. According to news reporting originating in Amsterdam, Netherlands, by NewsRx journalists, research stated, "Breast cancer is a heterogeneous disease that can be subdivided into different groups, based on gene expression profiles or clinicopathological characteristics such as estrogen receptor (ER), progesterone receptor (PR) and human epidermal growth factor receptor 2 (HER2) expression. The expression of these receptors has both prognostic and predictive value."
The news reporters obtained a quote from the research from the University of Amsterdam, "To improve breast cancer treatment, accurate methods for patient selection and response monitoring are required. One way to achieve this is by using molecular imaging, which can be used to measure the expression and accessibility of tumor-associated antigens in vivo, without the need of invasive biopsies. This review will focus on tumor-receptor imaging for currently approved targeted therapies and discuss the potential role of molecular imaging in the development of new therapeutic agents in breast cancer. Progress has been made in radionuclide imaging of ER, PR, HER2 and epidermal growth factor receptor (EGFR) expression, which can be used for treatment selection and response prediction to endocrine and other targeted therapy. Moreover, clinical studies have shown the feasibility for molecular imaging of the angiogenic pathway exploiting the expression of antigens closely associated with angiogenesis, such as alpha(v)beta(3) and VEGF."
According to the news reporters, the research concluded: "As proof of concept has been established, further research should be directed towards validation of the imaging methods and the impact on patient management."
For more information on this research see: Tumor-Receptor Imaging in Breast Cancer: A Tool for Patient Selection and Response Monitoring. Current Molecular Medicine, 2013;13(10):1506-1522. Current Molecular Medicine can be contacted at: Bentham Science Publ Ltd, Executive Ste Y-2, PO Box 7917, Saif Zone, 1200 Br Sharjah, U Arab Emirates. (Bentham Science Publishers - www.benthamscience.com; Current Molecular Medicine - www.benthamscience.com/cmm/index.htm)
Our news correspondents report that additional information may be obtained by contacting S. Heskamp, University of Amsterdam, Academy Med Center, Dept. of Med Oncol, NL-1105 AZ Amsterdam, Netherlands. Additional authors for this research include H.W.M. van Laarhoven, W.J.G. Oyen, W.T.A. van der Graaf and O.C. Boerman (see also Oncology).
Keywords for this news article include: Antigens, Europe, Oncology, Amsterdam, Treatment, Immunology, Netherlands, Therapeutics, Breast Cancer, Nanotechnology, Women's Health, Molecular Imaging, Biological Factors, Emerging Technologies
Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2014, NewsRx LLC